Study of SAA1 Levels in Blood and Tissue to Predict Rapid Tumor Growth in Cancer Patients Undergoing Immunotherapy

What this Trial Is About

Researchers are conducting a prospective cohort study to evaluate the reliability of plasma and tissue SAA1 levels as a marker to predict hyperprogression in cancer patients undergoing immunotherapy. Hyperprogression is a rapid tumor growth occurring in some patients early in immunotherapy, leading to poor prognosis and reduced quality of life. Identifying high-risk groups early is crucial, as no effective treatments or biomarkers currently exist for this condition. This observational study involves patients diagnosed with various malignant tumors, including nasopharyngeal carcinoma, head and neck tumors, lung, breast, stomach, colorectal, glioma, esophageal, liver, bile duct, cervical, prostate, and bladder cancers. Participants will all be treated with immune checkpoint inhibitors. The study will collect clinical tissue and blood samples for sequencing, proteomics, and metabolomics analysis to measure SAA1 levels. Participants will be monitored over a period of up to three years to assess outcomes such as incidence of hyperprogression within two years, as well as event-free survival, progression-free survival, and overall survival over three years. The study includes evaluations of patient performance status and treatment adherence. Researchers will track these measures to better understand the predictive value of SAA1 for hyperprogression in pan-cancer patients receiving immunotherapy.

Plasma and Tissue SAA1 Levels in Cancer Patients to Predict Hyperprogression of Immunotherapy